1Cademy - Discussion for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products

Concept

Discussion for the Inactivated Whole Virus Vaccine by Wuhan Institute of Biological Products

The vaccine was well tolerated and produced no vaccine related serious adverse effects. The incidence rate was 15% among all participants, which was lower than other current vaccines in trial. This could mean that an inactivated whole virus vaccine is a safer option, or it could be influenced by the small sample sizes of the current stage of testing.
The neutralizing antibody response results suggest that a longer interval between the first and second administration produced higher responses than a shorter interval. The observed increase in antibody titers after the second injection and again after the third suggest that a booster is needed for this vaccine. However, more time and information is needed to determine the exact intervals and times for booster administration.
Comparison to other published COVID-19 vaccine trials showed that the PRNT assayed antibody titers were comparable to the other studies. There are some drawbacks as the assay method is different and some results could not be compared.
Some studies have indicated that the antibody titers decline over time while others indicated that long-lasting memory T cells are still reactive years after exposure. There is not enough information about the vaccine yet to determine how long the antibodies last, so the participants will be followed up with in a year.